Details
| Stereochemistry | EPIMERIC |
| Molecular Formula | C20H21N7O6.2Na |
| Molecular Weight | 501.4036 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[Na+].[H][C@@](CCC([O-])=O)(NC(=O)C1=CC=C(C=C1)N2CC3CNC4=C(N3C2)C(=O)NC(N)=N4)C([O-])=O
InChI
InChIKey=DIAFTFLDTRCVOX-RIWFDJIXSA-L
InChI=1S/C20H23N7O6.2Na/c21-20-24-16-15(18(31)25-20)27-9-26(8-12(27)7-22-16)11-3-1-10(2-4-11)17(30)23-13(19(32)33)5-6-14(28)29;;/h1-4,12-13H,5-9H2,(H,23,30)(H,28,29)(H,32,33)(H4,21,22,24,25,31);;/q;2*+1/p-2/t12?,13-;;/m0../s1
Folitixorin, a thymidylate synthase inhibitor is a substrate used by the enzyme methylenetetrahydrofolate reductase (MTHFR) to generate 5-methyltetrahydrofolate. Folitixorin was studied in clinical trials for the treatment of breast cancer, metastatic colorectal cancer and for the treatment of advanced pancreatic cancer. Folitixorin had been granted orphan drug status for the treatment of pancreatic cancer in both the U.S. and EU. However, further development of this drug was discontinued.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
136245568
Created by
admin on Fri Dec 15 16:24:16 GMT 2023 , Edited by admin on Fri Dec 15 16:24:16 GMT 2023
|
PRIMARY | |||
|
133978-76-4
Created by
admin on Fri Dec 15 16:24:16 GMT 2023 , Edited by admin on Fri Dec 15 16:24:16 GMT 2023
|
PRIMARY | |||
|
172V4KO1N5
Created by
admin on Fri Dec 15 16:24:16 GMT 2023 , Edited by admin on Fri Dec 15 16:24:16 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
